Insider filing · MBX

P. Kent Hawryluk bought $273K of MBX Biosciences (MBX)

Executed Oct 20 2025, disclosed Oct 21 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Oct 21 2025), the stock returned +78.0% (delay-adjusted); from the execution session (Oct 20 2025), +92.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

PH P. Kent Hawryluk President & CEO profile →

P. Kent Hawryluk (President & CEO) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in MBX. Across 2 priced purchase filings, the average 21-session return was +55.1% from execution and +43.3% from disclosure (delay-adjusted; derived). The largest single filing was $526K of MBX (18,500 sh × $28.41, as filed), executed Mar 13.

MBX MBX MBX · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→